BHCM
IRD

Brevan Howard Capital Management’s Opus Genetics IRD Stock Holding History

Brevan Howard Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61,313
Closed -$279K – 2680
2026
Q1 		$279K Buy
+61,313
New +$212K ﹤0.01% 1672

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brevan Howard Capital Management's IRD Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Opus Genetics (IRD) in Q2 2026, closing a stake of 61,313 shares — an estimated $279K sold.

Brevan Howard Capital Management first reported a position in IRD in Q1 2026 and held it in 1 quarter. The position peaked at $279K in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Opus Genetics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 61,313 Opus Genetics shares in Q2 2026, an estimated $279K.
  • Brevan Howard Capital Management first reported a position in Opus Genetics in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Opus Genetics position peaked at $279K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.